Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA).

Full DD Report for SNOA

You must become a subscriber to view this report.


Recent News from (NASDAQ: SNOA)

Sonoma Pharmaceuticals Announces Second Quarter FY 2019 Financial Results and Conference Call
PETALUMA, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced that financial results for its fiscal year 2019 second quarter, ended September 30, 2018, will be released after the U.S. markets close on November 8, 2018.  The earnings rel...
Source: GlobeNewswire
Date: November, 01 2018 07:05
Sonoma Pharmaceuticals Announces Newly Published Results from Study of Hypochlorous Acid in Management of Hypertrophic and Keloid Scars
PETALUMA, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced newly published results from a study into the use of the company’s proprietary Performance Stabilized HOCl TM (hypochlorous acid) for the management of scars. The newly p...
Source: GlobeNewswire
Date: October, 25 2018 07:05
Sonoma Pharmaceuticals Appoints Phillipe Weigerstorfer to Board of Directors
PETALUMA, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced the appointment of Philippe Weigerstorfer to the company’s board of directors.  Weigerstorfer brings extensive pharmaceutical and dermatology experience to Sonoma...
Source: GlobeNewswire
Date: September, 19 2018 07:05
Sonoma Pharma's HOCI shows positive effect in acne study
Results from study evaluating Sonoma Pharmaceuticals' (NASDAQ: SNOA ) topical high-strength Performance-Stabilized HOCI in patients with mild-to-moderate acne vulgaris showed a treatment effect. The data were presented at the Practical Symposium Dermatology Conference in Colorado. More ...
Source: SeekingAlpha
Date: August, 28 2018 08:21
Sonoma Pharmaceuticals Announces Results from Study of Sonoma's Performance-Stabilized HOCl(TM) (Hypochlorous Acid) in Management of Acne Vulgaris
PETALUMA, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced that results from a study into the use of the company’s proprietary high-strength Performance-Stabilized HOCl TM in the management of acne vulgaris were presented at the ...
Source: GlobeNewswire
Date: August, 28 2018 07:05
Midday Gainers / Losers (08/10/2018)
Gainers: TMSR +50% . AWX +48% . MDLY +45% . TTD +35% . CORI +22% . SNOA +21% . OSTK +19% . PVG +18% . CKPT +18% . TRUE +17% . More news on: TMSR Holding Co., Ltd., Avalon Holdings Corporation, Medley Management, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 10 2018 12:38
Sonoma Pharma rebounds 20%
Thinly traded nano cap Sonoma Pharmaceuticals ( SNOA +20.1% ) is up on more than double normal volume, albeit on turnover of only 177K shares, as it tries to break free of a long-term downtrend that began in Q1 2017. More news on: Sonoma Pharmaceuticals, Inc., Healthcare stocks news, Sto...
Source: SeekingAlpha
Date: August, 10 2018 12:04

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-141.751.531.751.47102,352

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0723,34643,90853.1703Short
2018-12-0632,30746,52769.4371Short
2018-12-0436,69157,65063.6444Short
2018-12-0334,95747,01474.3544Short
2018-11-3015,40632,01748.1182Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SNOA.


About Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)

Logo for Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)

Not available

 

Contact Information

 

 

Current Management

  • James Schutz / CEO
    • James Schutz served as our vice president of corporate development and general counsel since August , as a director since May and corporate secretary since June . He was appointed CEO in February . Mr. Schutz was formerly the general counsel of Jomed, Inc. until when he orchestrated the sale of Jomed to Abbott Laboratories NYSE: ABT and Volcano Therapeutics NASDAQ: VOLC, now part of Royal Philips, NYSE PHG . Mr. Schutz received a B.A. in economics from the University of California, San Diego and a J.D. from the University of San Francisco School of Law.
  • Robert Miller / CFO, COO
    • Robert Miller has served as our chief financial officer since June and was a consultant to us from March to May . Mr. Miller has served as a director of Scanis, Inc. since and served as acting chief financial officer from to June . He was a chief financial officer consultant to Evit Labs from June to December , Wildlife International Network from October to December , Endoscopic Technologies from November to March , Biolog from January to December and Webware from August to August . Prior to this, Mr. Miller was the chief financial officer for GAF Corporation, Penwest Ltd. and Bugle Boy and treasurer of Mead Corporation. He received a B.A. in economics from Stanford University and an M.B.A. in finance from Columbia University.
  • Robert Northey, Ph.D / VP, R amp D
    • Robert Northey, Ph.D. has served as our director of research and development since July . Dr. Northey served as a consultant to us from May to June . From August until June , he was an assistant professor in the paper science and engineering department at the University of Washington. Dr. Northey received a B.S. in wood and fiber science and a Ph.D. in wood chemistry, each from the University of Washington.

Current Share Structure

  • Market Cap: $18,077,012 - 05/18/2018
  • Issue and Outstanding: 4,732,202 - 02/09/2018

 


Recent Filings from (NASDAQ: SNOA)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: July, 27 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: July, 17 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: June, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 05 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 06 2018

 

 


Daily Technical Chart for (NASDAQ: SNOA)

Daily Technical Chart for (NASDAQ: SNOA)


Stay tuned for daily updates and more on (NASDAQ: SNOA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: SNOA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SNOA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SNOA and does not buy, sell, or trade any shares of SNOA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/